AT&T Inc.

According to the Complaint, the Company made false and misleading statements to the market. AT&T increased prices for DirecTV Now service while discontinuing promotional discount offers for the service at the same time. This resulted in existing customers leaving the service when their discount expired, and new customers avoiding the service altogether based on high prices. Based on these facts, the Company’s public statements were false and materially misleading. When the market learned the truth about AT&T, investors suffered damages.

-->

Stamps.com, Inc.

According to the Complaint, the Company made false and misleading statements to the market. Stamps.com’s financial performance was based upon the manipulation of a USPS program that utilizes up to $235 million each year. This caused the Company’s business to be unsustainable and its financial results to be misleading. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Stamps.com, investors suffered damages.

-->

WuXi PharmaTech (Cayman) Inc.

According to the Complaint, the Company made false and misleading statements to the market. WuXi failed to provide material information and made misrepresentations in public statements to investors, making it impossible for them to make an informed decision about the proposed merger between the Company and New WuXi Life Science Limited and WuXi Merger Limited for approximately $3.62 billion. The Company planned to spin-off the subsidiaries as publicly-traded entities for their own gain. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about WuXi, investors suffered damages.

-->

Corbus Pharmaceuticals Holdings, Inc.

According to the Complaint, the Company made false and misleading statements to the market. Corbus inappropriately changed the primary efficacy endpoint of its clinical trial for its drug candidate Lenabasum. The change took place after the trial’s results were unblinded to the Company. Corbus replaced the two-sided p value traditionally reported in clinical trials with a one-sided p value, in an effort to conceal the study result’s lack of statistical significance. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Corbus, investors suffered damages.

-->

Venator Materials PLC

According to the Complaint, the Company made false and misleading statements to the market. Venator’s Pori facility suffered a fire that damaged the property much worse than was disclosed to investors, leaving it beyond repair. The cost of the fire exceeded $1 billion, far beyond the limits of the Company’s insurance policy. The Company incurred massive fees in a futile effort to expedite repairs to the facility. Venator lost about 80% of the production capacity of the Pori facility. At the same time, the Company’s reported annual Titanium Dioxide production capacity had been inflated by about 15%. The Company paid over $600 million in restructuring charges and expenses associated with the closure and replacement of the Pori facility. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Venator, investors suffered damages.

-->

BrightView Holdings, Inc.

According to the Complaint, the Company made false and misleading statements to the market. A considerable number of Brightview’s contracts were performing poorly and generating undesirable costs for the Company. Brightview designed a “managed exit” strategy to end unprofitable contracts and low margin business arrangements. This strategy negatively impacted revenue throughout 2018 and has continued to negatively impact revenues in 2019. Based on these facts, the Company’s Registration Statement was false and materially misleading throughout the IPO. When the market learned the truth about BrightView, investors suffered damages.

-->

Syneos Health, Inc.

According to the Complaint, the Company made false and misleading statements to the market. Syneos’ failed to maintain adequate internal controls over financial reporting. Due to the Company’s poor controls, it became the target of an SEC investigation of its revenue accounting policies and other related items. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Syneos, investors suffered damages.

-->

AVEO Pharmaceuticals, Inc.

According to the Complaint, the Company made false and misleading statements to the market. The 2013 TIVO-3 trial for AVEO’s lead candidate drug, tivozanib, was not adequately designed to address concerns about survivability. The drug did not have sufficient survival data to gain FDA approval after its initial rejection. The lack of survival data put the Company at risk for additional FDA approval delays. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about AVEO, investors suffered damages.

-->

Revolution Lighting Technologies, Inc.

According to the Complaint, the Company made false and misleading statements to the market. Revolution Lighting improperly recognized revenue for various transactions, resulting in the Company’s financial statements being misstated. Revolution failed to maintain adequate controls on its financial reporting. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Revolution Lighting, investors suffered damages.

-->

Arlo Technologies, Inc.

According to the Complaint, the Company made false and misleading statements to the market. Arlo’s new battery for the Company’s Ultra camera systems suffered from flaws and quality issues. These problems resulted in a shipping delay in the Ultra cameras. The delays endangered Arlo’s product from reaching the market for the holiday season, and allowed competitors to capitalize on the issue, gaining market share from the Company. At the same time, Arlo’s customers experienced problems with the product including excessive battery drain. The battery issues were likely to negatively impact the fourth quarter 2018 financial results. Based on these facts, the Company’s Registration Statement was false and materially misleading. When the market learned the truth about Arlo, investors suffered damages.

-->